Harnessing the power of nature to improve lives

Novel anticancer and wound healing pharmaceuticals for human and veterinary markets - discovery, development and commercialisation.
Our lead drug, tigilanol tiglate, is a small molecule anticancer pharmaceutical targeting a range of solid tumours across multiple species.
Tigilanol tiglate (branded STELFONTA®) is approved to treat canine mast cell tumours, and is marketed in USA, UK, EU and Australia.
Our next lead, EBC-1013, is in development for the treatment of debilitating acute and chronic wounds.

Our Company
We discover and develop plant-derived cell signalling molecules to address challenging medical conditions in humans and companion animals
The simultaneous development of products for both veterinary and human application enables early validation of technology, reducing risks for human development, while generating early revenues through quicker to market veterinary products.
Meet our team

Executive Chair

Dr Susan Foden
MA D.Phil.
Executive Chair
Dr Susan Foden brings over 20 years of experience as director on the boards of small and medium-size private and public healthcare companies in the UK, Norway, Germany and Belgium.
Recent board positions include BTG plc (acquired by Boston Scientific in 2019), and Vectura Group plc where she served for over 10 years as Senior Independent Director and Chair of the Remuneration Committee until 2019. Susan also chaired, and was a director of, BerGenBio ASA up to its initial public offer on the Oslo Bohrs in 2015 and Neurocentrx.
Currently, Susan is the non-executive chair of Evgen Pharma plc, a non-executive director of Laverock Therapeutics Ltd, an Investment Committee member of CD3, the drug discovery initiative between the European Investment Fund and the University of Leuven in Belgium, and a trustee of the Roslin Foundation in Edinburgh.
Susan's background is in biochemistry and with an MA and DPhil in Natural Sciences from the University of Oxford. In 1983 Susan joined the UK’s first biotech company, Celltech Ltd and headed up Academic Liaison, establishing some of the early precedents of academic/ biotech partnering and intellectual property development and in-licensing. In 1987 she established CRCT, the technology transfer and development company of what was then Cancer Research Campaign, (now CRT/Cancer Research UK (CRUK)). Over the next 12 years, CRCT was responsible for the development and partnering many programs, significantly Temodal, Abiraterone (with BTG) and some of the early PARP inhibitors from which CRUK has benefitted from many years of royalty flow. Spin-out companies Cyclacel, Kudos and Spriogen Ltd also came from CRCT.
Outside the UK, CRCT set up Cancer Research Ventures and among others, established links with cancer research centres in Germany, Denmark and New Zealand.
In 2000, Susan joined the London healthcare VC firm, Merlin Biosciences as an Investor Director and was a director on several Merlin investee company boards including the oncology-focused companies, BioVex (acquired by Amgen 2011), and Piramed (acquired by Roche 2008).
Susan was appointed as a director of QBiotics Group on 14 October 2019.

Executive Director Strategic Alliances and Investor Relations

Dr Victoria Gordon
B.App.Sc. (Hons.) PhD GAICD
Executive Director Strategic Alliances and Investor Relations
Dr Victoria Gordon brings to QBiotics Group a sound scientific background combined with broad business management experience and a strong commercial emphasis. Victoria left her position as a research scientist in chemical ecology with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to establish EcoBiotics Pty Ltd (EcoBiotics) in 2000, followed by QBiotics Pty Ltd in 2004. Victoria also governed the merger of EcoBiotics and QBiotics to form the QBiotics Group in 2017. Victoria has been Managing Director and CEO of EcoBiotics/the QBiotics Group since their inception. Victoria’ recent additional board experience includes Non-executive Director of Biopharmaceuticals Australia and Non-executive Director and Non-executive Chairman of the Australian Rainforest Foundation. Victoria’s relevant committee memberships include two consecutive terms of the Queensland Government Biotechnology Advisory Council, Federal Government Expert Forum on Biomedicine, Federal Government Expert Forum on Environmental Biotechnology, and the Queensland Government Science Education Taskforce. In 2004 Dr Gordon was presented an award by the Queensland Premier for her service to the biotechnology industry.
Victoria has broad experience in the management of commercial research for Boral Timber Division, then one of Australia’s largest plantation forestry companies, has owned and managed a number of small businesses and has held lecturing positions in industrial mycology and plant tissue culture at the University of Tasmania.
Victoria holds a PhD in Microbiology, Bachelor of Applied Science in Chemistry and Biology (Honours), Diplomas in Human and Animal Health, and is a Graduate of the Australian Institute of Company Directors.
Victoria is a Director of QBiotics Group and its wholly-owned subsidiary companies, QBiotics Pty Ltd, EcoBiotics Pty Ltd, QBiotics Netherlands B.V. and QBiotics UK Limited.

Executive Director and Chief Scientific Officer

Dr Paul Reddell
B.Sc. (Hons.) PhD FAICD
Executive Director and Chief Scientific Officer
Paul brings to the Company expert scientific knowledge combined with extensive practical experience in leadership, resourcing, management and commercialisation of complex multi-institutional research and development projects. Paul is co-founder of EcoBiotics and QBiotics and has been CSO of both companies since their inception.
Prior to co-founding EcoBiotics in 2000, Paul gained an international reputation for his scientific expertise in tropical forest ecology and management. During that time, he held senior leadership positions as a Senior Principal Research Scientist and Program Leader at CSIRO’s Tropical Forest Research Centre and later as Principal Plant Ecologist for an environmental consulting business in the Rio Tinto group of companies.
Paul holds a PhD in Forest Ecology and a Bachelor of Science (1A Honours) from the University of Western Australia. He has been a Fellow of the Australian Institute of Company Directors since 2007.
Paul is a Director of QBiotics Group and its wholly-owned subsidiary companies, QBiotics Pty Ltd, EcoBiotics Pty Ltd, QBiotics Netherlands B.V. and QBiotics UK Limited.

Non-executive Director

Mr Andrew Denver
B.Sc. (Hons.) MBA FAICD
Non-executive Director
Mr Andrew Denver has extensive expertise that is relevant to QBiotics Group, including assisting in the commercialisation of several technology companies. Andrew has wide-ranging knowledge of the life sciences industry of which QBiotics Group is a part including, risk assessment, financial reporting and general management, which are important in the success of QBiotics Group’s business.
Andrew was the interim Chief Executive Officer of Universal Biosensors, Inc. (UBI) from September 2010 to May 2011, a director of UBI from December 2002 to August 2017 and Chairman of UBI from September 2005 to August 2017. Andrew was Non-Executive Director of Cochlear Ltd and a member of the Audit & Risk, Medical Science, Technology & Innovation and Nomination Committees of the Cochlear Ltd board, and Chairman of Speedx Pty Ltd (a molecular diagnostics company). Between 2002 and 2005, Andrew was President of Pall Asia, a subsidiary of Pall Corporation after the acquisition by Pall Corporation of US Filter’s Filtration and Separations business, where he was also President. Pall Corporation is a technology-based filtration, separation and purification multinational company.
Andrew is currently a non-executive director of Vaxxas Pty Ltd.
Andrew graduated from the University of Manchester with a Bachelor of Science Degree (Honours) in Chemistry and achieved a distinction in his MBA at the Harvard Business School and is a Fellow of the Australian Institute of Company Directors.
Andrew was previously a director of QBiotics and was appointed as a director of QBiotics Group on 1 November 2017.

Non-executive Director

Prof Bruce Robinson AC
MD M.Sc. FRACP FAHMS FAICD
Non-executive Director
Professor Bruce Robinson is an endocrinologist. He graduated from the University of Sydney in 1980 and then undertook studies for a Master of Science degree. His further molecular research work was performed at the Brigham and Women’s Hospital and the Children’s Hospital, Harvard Medical School from 1986–1989 and he was awarded a Doctor of Medicine from the University of Sydney in 1990. Bruce has developed and led the Cancer Genetics Laboratory since 1990 and has supervised over 35 doctoral and master’s students working on the genetic basis for tumour formation and gene therapy. He has published over 300 peer-reviewed scientific articles. In 2003, Bruce was awarded the Daiichi Prize by the Asia and Oceania Thyroid Association for this work on the pathogenesis of thyroid cancer.
Until early 2016, Bruce was Associate Dean (International) in the Faculty of Medicine at the University of Sydney and was Head of the Division of Medicine at the Royal North Shore Hospital from 1998–2006. Bruce also served on the Council of the Endocrine Society of Australia from 2001–2005. He is on the editorial board of the international journals Nature, Clinical Practice and Endocrinology and Thyroid. Bruce has a strong interest in furthering relations between Australia and Asia and he is the Founding Chairman of Hoc Mai, the Australia–Vietnam Medical Foundation, which sponsors and supports medical, nursing, allied health and scientific exchanges between Australia and Vietnam. Bruce was awarded the People’s Health Medal by the Vietnamese Government in 2008. He is a Fellow of the Australian Institute of Company Directors.
Bruce was the Chair of the Medicare Benefits Schedule (MBS) Review Taskforce, which considered how services could be aligned with contemporary clinical evidence and improve health outcomes for patients. Until 2021 he served as the Chair of the Council of National Health and Medical Research Council (NHMRC).
Bruce is Co-Head of the Cancer Genetics Laboratory at the Kolling Institute at the Royal North Shore Hospital, and the Dean of Medicine 2006–2016 at the University of Sydney.
Bruce currently holds non-executive director roles with ASX-listed healthcare companies Cochlear Limited and Mayne Pharma Limited. Professor Robinson was previously a director of QBiotics and was appointed as a director of QBiotics Group on 1 November 2017.

Non-executive Director

Mr Hamish Corlett
Non-executive Director
Mr Hamish Corlett is a Co-Founder and Partner at TDM Growth Partners, a private investments firm specialising in high growth companies globally. Hamish brings more than 20 years’ experience in investing and investment banking from multiple top-tier investment firms to his role on the QBiotics Board.
Hamish is currently a Non-executive Director of Somnomed Limited (ASX:SOM), a medical company providing treatment solutions for sleep-related breathing disorders. He is also Chair of Somnomed’s Remuneration Committee. Hamish has also been a Non-Executive Director of Tyro Payments Ltd (ASX:TYR) since April 2019.
Hamish holds a Bachelor of Commerce with Honours Class 1 (Accounting and Finance) from the University of Sydney and a Graduate Diploma of Counselling from the Australian College of Applied Psychologists.

Executive Director Strategic Alliances and Investor Relations

Dr Victoria Gordon
B.App.Sc. (Hons.) PhD GAICD
Executive Director Strategic Alliances and Investor Relations
Dr Victoria Gordon brings to QBiotics Group a sound scientific background combined with broad business management experience and a strong commercial emphasis. Victoria left her position as a research scientist in chemical ecology with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) to establish EcoBiotics Pty Ltd (EcoBiotics) in 2000, followed by QBiotics Pty Ltd in 2004. Victoria also governed the merger of EcoBiotics and QBiotics to form the QBiotics Group in 2017. Victoria has been Managing Director and CEO of EcoBiotics/the QBiotics Group since their inception. Victoria’ recent additional board experience includes Non-executive Director of Biopharmaceuticals Australia and Non-executive Director and Non-executive Chairman of the Australian Rainforest Foundation. Victoria’s relevant committee memberships include two consecutive terms of the Queensland Government Biotechnology Advisory Council, Federal Government Expert Forum on Biomedicine, Federal Government Expert Forum on Environmental Biotechnology, and the Queensland Government Science Education Taskforce. In 2004 Dr Gordon was presented an award by the Queensland Premier for her service to the biotechnology industry.
Victoria has broad experience in the management of commercial research for Boral Timber Division, then one of Australia’s largest plantation forestry companies, has owned and managed a number of small businesses and has held lecturing positions in industrial mycology and plant tissue culture at the University of Tasmania.
Victoria holds a PhD in Microbiology, Bachelor of Applied Science in Chemistry and Biology (Honours), Diplomas in Human and Animal Health, and is a Graduate of the Australian Institute of Company Directors.
Victoria is a Director of QBiotics Group and its wholly-owned subsidiary companies, QBiotics Pty Ltd, EcoBiotics Pty Ltd, QBiotics Netherlands B.V. and QBiotics UK Limited.

Executive Director and Chief Scientific Officer

Dr Paul Reddell
B.Sc. (Hons.) PhD FAICD
Executive Director and Chief Scientific Officer
Paul brings to the Company expert scientific knowledge combined with extensive practical experience in leadership, resourcing, management and commercialisation of complex multi-institutional research and development projects. Paul is co-founder of EcoBiotics and QBiotics and has been CSO of both companies since their inception.
Prior to co-founding EcoBiotics in 2000, Paul gained an international reputation for his scientific expertise in tropical forest ecology and management. During that time, he held senior leadership positions as a Senior Principal Research Scientist and Program Leader at CSIRO’s Tropical Forest Research Centre and later as Principal Plant Ecologist for an environmental consulting business in the Rio Tinto group of companies.
Paul holds a PhD in Forest Ecology and a Bachelor of Science (1A Honours) from the University of Western Australia. He has been a Fellow of the Australian Institute of Company Directors since 2007.
Paul is a Director of QBiotics Group and its wholly-owned subsidiary companies, QBiotics Pty Ltd, EcoBiotics Pty Ltd, QBiotics Netherlands B.V. and QBiotics UK Limited.

Chief Operating Officer

Dr Peter Schmidt
B.Sc. (Hons.), PhD
Chief Operating Officer
Dr Schmidt has considerable expertise in the development of drug candidates for submission to both the TGA in Australia and the FDA in the USA up to Clinical Phase III including preparation of CMC and Preclinical data packages required for IND submissions, and the clinical practices required during Clinical Phase I and II trials.
Peter’s human drug development expertise complements and strengthens QBiotics veterinary drug development team. Peter came to QBiotics from the drug discovery and development company Xenome Limited where he was Director of CMC and Preclinical Drug Development for 6 years. Prior to Xenome, Peter was Senior Scientist at Agen Biomedical for 7 years and Professional Officer at Radiopharmaceuticals Australian Nuclear Science and Technology Organisation for 8 years.
Peter holds a Bachelor of Science (Honours) and a PhD in Experimental Medicine.

Chief Financial Officer

Michael Wenzel
B.Com. FCA CIA GIA(Cert.) GAICD
Chief Financial Officer
Mr Wenzel has worked for EcoBiotics and QBiotics since 2011. Prior to this, Michael worked for over 13 years in the audit and advisory divisions of KPMG. During this time, Michael gained a wealth of experience across a range of industries, including biotechnology, as a senior engagement manager, key client contact, and quality control reviewer on a variety of external and internal audits of publicly listed companies, unlisted companies, foreign owned subsidiaries, government entities and not-for-profit entities.
Michael holds a Bachelor of Commerce, is a Fellow of Chartered Accountants Australia and New Zealand, a Certified Internal Auditor and an Associate Member of the Institute of Internal Auditors – Australia. Michael is a Certificated Member of the Governance Institute of Australia and a Graduate Member of the Australian Institute of Company Directors. Michael is also a Registered Company Auditor.

Chief Translational Research Officer

Dr Steven Ogbourne
B.Sc. (Hons.) PhD MAICD, Adjunct Associate Professor, University of the Sunshine Coast
Chief Translational Research Officer
Dr Ogbourne holds a PhD in Molecular Biology and a Bachelor of Science (Honours) in Plant Science. He is an Adjunct Professor at the University of the Sunshine Coast (UniSC) and a Graduate of the Australian Institute of Company Directors.
Steven brings to QBiotics expert scientific knowledge in the fields of biodiscovery and plant genetics, and significant experience in drug development having held leadership roles in both academic and pharmaceutical sectors.
Steven is an internationally recognised research scientist, having published over 60 peer-reviewed scientific articles, and has considerable expertise in small molecule drug development because of his senior role in the discovery, development and commercialisation of Picato® with Peplin Inc and LEO Pharma, and more recently in the development and commercialisation of STELFONTA®.
As recently as June 2022, Steven was Associate Professor, Plant Biotechnology at UniSC, where his research focussed on biodiscovery in therapeutic areas including cancer, wound-healing and anti-microbials and on the domestication of Fontainea picrosperma. Steven also has a passion for conservation and a significant component of his research focussed on the conservation of threatened species of plants and animals. Steven held the leadership role of Deputy Director of the Centre for BioInnovation at UniSC and continues to offer leadership through the Centre’s Advisory Board.
Steven joined the QBiotics executive team as Chief Translational Research Officer on 4 July 2022 and maintains an adjunct appointment at UniSC. Steven was previously a director of EcoBiotics and QBiotics Group.

Chief New Product Development Officer

Dr Sam Yurdakul
B.Sc. (Eng), PhD
Chief New Product Development Officer
Dr Yurdakul has over 30 years' experience leading product development across multiple therapeutic areas with Procter & Gamble, Boots Healthcare International, and Novartis. Most recently, as Director of Product Development & Regulatory Affairs and a member of the Executive Team with Ascension Healthcare, Sam led the development and commercialisation of products in the fields of haematology, pain management, and dermatology. Sam holds a PhD in Surface Chemistry from London Imperial College of Science, Technology and Medicine.

Chief Veterinary Officer

Dr Pamela Jones
DVM, Diplomate ACVIM (Oncology), Diplomate ACVR (Radiation Oncology)
Chief Veterinary Officer
Dr. Pamela Jones underwent her veterinary training in the United States at Colorado State University. She completed a one-year rotating internship in small animal medicine and surgery followed by a three-year oncology residency and a two-year residency in radiation oncology. She is board-certified by the American College of Veterinary Internal Medicine in medical oncology and by the American College of Veterinary Radiology in radiation oncology. She has enjoyed specialty practice in the southwestern United States and has served in several capacities in the pharmaceutical industry including her current position as Chief Veterinary Officer.

Chief Legal and Commercial Officer

Roberta Bozzoli
LLB, LLM (Intellectual Property), B Com
Chief Legal and Commercial Officer
As a Partner at Thomson Geer Lawyers, Roberta specialised in intellectual property, corporate and commercial law. Most recently Roberta provided advice to pharma, government, universities, research institutes and life sciences entities in relation to research and development arrangements, commercialisation, licensing, exploitation of intellectual property clinical trials, distribution and manufacturing agreements, mergers and acquisitions. Roberta has acted on behalf of QBiotics for over 20 years, providing legal advice to achieve our key corporate, research and commercial milestones.
Roberta has been recognised by her peers as ‘Lawyer of the Year’ by Best Lawyers in Australia in the areas of Biotechnology Law (2019 and 2022) and Intellectual Property Law (2020) in Brisbane. She has also been recognised generally by Best Lawyers in Australia in the areas of Biotechnology Law, Intellectual Property Law, Life Sciences Practice and Information Technology Law. Roberta has also been recognized in Doyle’s Guide as a recommended lawyer in Queensland in Intellectual Property.
Roberta holds a Bachelor of Laws, a Master of Laws (Intellectual Property) and a Bachelor of Commerce.

General Counsel

Ebru Davidson
BSc, JD (Hons.) AGIA AGC
General Counsel
Ebru is a former partner at Thomson Geer Lawyers and brings over 14 years experience in equity capital markets, private and public mergers and acquisitions, corporate transactions and corporate governance. She also has extensive experience in advising listed and unlisted entities on compliance and regulatory matters working closely with the Australian Securities and Investment Commission and Australian Securities Exchange.
Ebru holds a Bachelor of Science degree from the University of Melbourne, a Juris Doctor (Honours) from Bond University. Ebru is an Associate Member of the Governance Institute of Australia having completed a Graduate Diploma of Applied Corporate Governance.

Business Development Manager

Dr Tracey Mynott
B.Agr.Sc. (Hons.), PhD
Business Development Manager
Dr Mynott has worked for QBiotics since 2019 and has 30 years’ experience in drug development and technology transfer in academia and the biotechnology industry. During Tracey’s career she has gained broad knowledge and experience in initiating and conducting fundamental biological research, drug discovery and project management, as well as devising and implementing drug development and clinical programs, licensing and intellectual property protection and business strategies.
Having co‐founded four biotechnology companies, Tracey has experience in strategic and operational matters, risk management, legal, due diligence, and compliance issues, capital raising and investor relations. In Tracey’s previous role at Anatara, she devised, secured strategic partnerships and executed the development plan for its lead product Detach® through to its marketing approval and a global licensing deal with Zoetis, Inc.
Tracey holds a Bachelor of Agricultural Science (Honours) and a PhD in Pathogenesis of Enteric Infections.

Chief Medical Officer

Dr Marissa Lim
BMedSc, MBBS, MBA
Chief Medical Officer
Dr Marissa Lim is a registered medical practitioner in Victoria, specialising in Anaesthesia. With a substantial two-decade background in the Pharmaceutical Industry, she brings a wealth of experience to QBiotics.
Marissa's expertise encompasses drug development, clinical research, ethics, compliance, and product launch preparedness. Her proficiency in clinical development spans from Phase 1 to Phase 3, where she has been instrumental in designing clinical trials and collaborating with key opinion leaders across diverse therapeutic areas.
Marissa has led various Medical Departments, playing a pivotal role in shaping crucial medical strategies, overseeing product launches, and ensuring stringent drug safety and compliance measures. Marissa’s previous roles include Country and APAC Regional Medical Director at Vifor Pharma and Ipsen, as well as Global Medical Director at Telix Pharmaceuticals.
Her contributions extend beyond her professional responsibilities; for seven years, she actively participated as a voting member of the Medicines Australia Code of Conduct Committee, showcasing her unwavering commitment to ethical practices.
Marissa's academic journey is equally impressive, holding a Medical degree, a Bachelor of Medical Science with Honours, and an MBA from Monash University. These academic accomplishments reflect her dedication to both the medical field and comprehensive leadership.
With a steadfast focus on ethical patient care and advancements in medicine, Dr. Marissa Lim exemplifies professionalism and humility. Her journey is characterised by a sincere dedication to her craft, and she continues to contribute to the healthcare landscape with her blend of experience, knowledge, and a commitment to excellence.
Partner with us
Partnerships are fundamental to our business
We develop strategic partnerships and collaborations with companies and organisations to unlock the full potential value of our products and research pipeline.
If you are interested in exploring opportunities for partnerships or collaborations with QBiotics, please contact partners@qbiotics.com.
Lead molecule in the clinic and a pipeline for the future
QBiotics has identified significant unmet medical needs and market opportunities in a range of therapeutic areas.



